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ABSTRACT- Word count 250 (limit 250) 
Background 
A recent meta-analysis of global research found cancer patients living in rural locations are 5% 
less likely to survive than their urban counterparts, a survival disadvantage that has never 
been satisfactorily explained. 
 
Aims 
[1] To describe and compare primary-care involvement in the diagnosis of cancer between 
rural and urban patients in Scotland. 
 
[2] To compare the length of key diagnostic pathway intervals between rural and urban cancer 
patients in Scotland.  
 
Methods 
Participating GPs in the Scottish National Cancer Audit of cancer diagnosis (2017) collected data from 
primary-care medical records on the diagnostic pathway of patients diagnosed in 2014. Residential 
postcodes designated the patients as rural or urban dwellers.  Key cancer diagnostic pathway intervals 
(primary, diagnostic, secondary, and treatment) were compared using binary logistic regression. 
Descriptive analysis included comparison of patient characteristics, and routes to diagnosis. 
 
Results 
73 Scottish general practices provided data on 1,905 cancer diagnoses. Rural patients did not 
have higher odds of prolonged diagnostic intervals compared to urban patients but were 
significantly more likely to have had a cancer alarm feature at presentation and three or more 
primary-care consultations prior to referral. Rural GPs were significantly more likely to 
perceive an avoidable delay in their patient’s diagnostic pathway.  
 
Conclusion 
There was no evidence that rural patients were more likely to be subject to prolonged cancer 
diagnostic delays than urban patients. Rural patients may experience primary care differently 
in the lead-up to a cancer diagnosis. The effect on outcome is probably negligible, but further 
research is required to confirm this. 
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Rural-dwellers who develop cancer in Scotland (Campbell et al, 2000) and other developed 
countries have poorer outcomes (Coory et al, 2006;  Pozet et al, 2008; Underhill et al, 2006; 
Westeel et al, 2007, Murage et al, 2018) but reasons why are unclear.  
 
A systematic review and meta-analysis of studies comparing cancer survival between urban 
and rural residents found rural-dwellers were five per cent less likely to survive cancer than 
urban counterparts, with little evidence on underlying mechanisms (Carriere et al, 2018).  The 
review included a narrative synthesis of potential explanations which concluded causes were 
obscure and likely to be complex and multifactorial. 
Other research studies exploring urban versus rural cancer survival have been less definitive 
in establishing a rural cancer disadvantage, but are perhaps suggestive as to potential 
mechanisms. For example international studies comparing urban-rural survival in breast, lung 
and pancreatic cancer found that a rural survival disadvantage became non-significant once 
treatment received was controlled for (Mitchell et al, 2011, Johnson et al, 2014;  Kirkegård et 
al, 2018). Also, studies from Australia and New Zealand concluded that their demonstration 
of no difference in rural-urban cancer survival reflected deliberate policies to counteract 
centralization of cancer services in urban areas (Bennett et al, 2007; Dasgupta et al, 2012). 
Recent research in Scotland provides further new insight. Turner et al (2017), using 
geographic information systems (GIS) to locate patients with respect to healthcare services, 
explored associations between travel burden and cancer outcomes. Analysis including more 
than 12,000 cancer patients from across Northeast Scotland revealed a rural paradox. The 
most remote patients living more than an hour's travel from their cancer treatment centre 
were treated more quickly, but were significantly less likely to survive to one-year compared 
to those living closer, even adjusting for advanced cancer at presentation. This contradiction 
has not been satisfactorily explained. 
It has been argued that initiatives to improve rural health should not focus solely on 
determining and responding to area-based explanations for rural inequalities and should 
instead target all potential risk determinants collectively (Smith et al, 2008). However 17.4% 
of Scotland’s population (one million people) live rurally (Scottish Government, 2018) and 
such comprehensively unfocused policies risk being extremely costly, inefficient and 
ineffective. It seems prudent, therefore, to take every opportunity to elucidate precise targets 
for intervention.  
In 2016-17, Cancer Research UK, together with NHS partners, the Royal College of General 
Practitioners (RCGP) and Macmillan Cancer Support, conducted a National Cancer Diagnosis 
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Audit (NCDA) in Scotland (Murchie et al, 2020). The aim of the NCDA was to understand 
primary care cancer diagnosis. This audit collected granular data on diagnostic pathway from 
primary care medical records on cancer patients diagnosed in 2014, supplemented by linkage 
to the Scottish Cancer Registry. This paper now compares 1,905 cancer patients included in 
the Scottish NCDA with respect to demographic characteristics, routes to diagnosis and key 
cancer pathway intervals to gain new information on potential reasons for Scotland’s 
geographical cancer inequality. The NCDA provided a representative sample of cancers 
diagnosed in Scotland in 2014 with respect to key demographics, details of which are available 





2.1 Study population and data collection 
In late 2016 the Information Services Division (ISD), NHS Scotland, assigned all incident cancer 
cases from the whole of 2014 (excluding non-melanoma skin cancer) to their registered 
general practice at diagnosis using the Scottish Cancer Registry. NCDA participants were 
volunteer practices recruited following promotion by the RCGP, Cancer Research UK and 
Macmillan Cancer Support. Registration included signing Caldicott Data Release Forms to 
permit data-sharing with ISD. Approved practice leads (usually a GP) were securely sent pre-
prepared Excel data-collection forms for eligible cancer diagnoses. Practices returned de-
identified forms to ISD using secure NHS email. Forms were issued and returned between 
February and June 2017. 
 
The eight-sectioned excel form, detailing patients’ pathways to cancer diagnosis were pre-
populated with Scottish Cancer Registry and Cancer Waiting Times data.  This included cancer 
type,  stage,  date of cancer diagnosis, date of death, date of receipt of cancer referral from 
primary care, date of start of treatment, level of urgency, source of referral and method of 
first detection (Appendix I). Primary-care held medical records were used to validate dates 
and vital status.  Residential postcodes enabled the Scottish Index of Multiple Deprivation 
(SIMD) grouped into one of five categories using quintiles and Scottish Government 2-fold 
and 6-fold Urban-Rural Classifications to be assigned to each patient(Scottish Government, 
2018; Scottish Government, 2018).(Figure 1) 
 
The form also gathered data on patient socio-demographic characteristics; presence of any 
co-morbidities (categorised into 0, 1-2, and 3 or more); number of consultations before 




The analysis reported adopted similar data-definitions as those reported in the Scottish NCDA 
baseline paper (Murchie et al, 2020). Symptoms and positive signs recorded in NCDA as having 
been present at first consultations were mapped onto site-specific Scottish Referral 
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Guidelines for Urgent Suspected Cancer by PM (Scottish Executive, 2014). The presence at 
first presentation of any single guideline symptom or positive sign for any cancer according 
to the Scottish guidelines was recoded to indicate “at least one alarm feature at 
presentation.” Primary care-led investigations were grouped into blood, urinary, imaging, 
endoscopy and other tests. 
 
Key cancer pathway intervals, (primary care, diagnostic, secondary care and treatment 
intervals) were calculated using available dates (Weller et al, 2012). Primary care interval (PCI) 
measures number of days from the date of first relevant presentation in primary care to the 
date of first GP referral. Diagnostic interval (DI) measures number of days from the first 
relevant presentation in primary care to date of cancer diagnosis. Secondary care interval 
(SCI) measures the number of days between GP referral to date of cancer diagnosis, and 
treatment Interval (TI) measures number of days from diagnosis to date treatment started. 
Any intervals of <0 and >730 days were excluded from further analysis. Medians and inter-
quartile-ranges were calculated, as was the proportion of patients with intervals of more than 
60 or 90 days. 
 
The median number of consultations prior to referral was calculated, as was proportion of 
patients requiring three or more consultations before referral. Based on participating GPs’ 
perception where they subjectively judged whether in hindsight, an “avoidable delay” had 
occurred, we described the health care setting and stage in the diagnostic pathway where the 
delay was attributed to. 
 
In subsequent analysis the distribution of categorical variables was compared between rural 
and urban groups (using the Scottish 2-fold classification) using contingency tables and Chi-
squared tests. Median pathway intervals were combined using appropriate non-parametric 
tests. To explore relatively prolonged pathway intervals for urban and rural participants eight 
binary variables >60 days or >90 days (yes or no) for each of the four key intervals (primary 
care, secondary care, diagnostic and treatment interval) were derived. Subsequently the 
univariate odds (rural vs urban) of a delay >60 and >90 days were calculated using univariate 
binary logistic function in SPSS V.23 (IBM, Armonk, NY, USA). Subsequently, multivariable 
analysis was conducted to calculate the adjusted odds (rural vs urban) for each interval being 
prolonged >60 and >90 days using the same SPSS V.23 function, but this time adding cancer 
site, deprivation, number of comorbidities, gender, and presence of at least one alarm feature 
to adjust for potential confounding. A further sensitivity analysis was conducted using the 
Scottish 6-fold urban rural classification (Appendix II).  
 
3. RESULTS 
Seventy-three Scottish general practices (7.7% of all Scottish general practices in 2017) submitted data 
on 1,905 cancer diagnoses (6.0% of cancers diagnosed in Scotland in 2014). Characteristics of this 
patient sample show that 76.4% were urban-dwelling and 23.6% were rural-dwelling. There 
were slightly more men (53.6%) than women in rural areas, and in urban areas, males 50.3%. 
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Age group distribution was similar in the two populations (rural median age 70 (IQR 60-78), 
urban 70 (IQR 60-77). Most rural patients tended to be from less deprived areas, SIMD 
categories 3 and 4, (68.2% v 30.7%). There were no great differences in cancer type apart 
from a slightly lower incidence in rural areas of lung cancer (15.1% v 20.0). Rural patients were 
also slightly more likely to have comorbidities. There was no significant variation in cancer 
stage at diagnosis (table 1).  
Detection of cancer and route to diagnosis 
There were no significant differences in how patients’ cancer was detected between urban 
and rural areas. For most patients this was through clinical presentation (urban 91.6%, rural 
92.7% respectively)(table 2).   
Compared with urban patients, fewer rural patients were referred routinely (9.3% v 11.1%) 
or through emergency referral (21.5% v 19.8%), more were referred through the urgent-not 
for suspected cancer (12.0% v 8.8%) and urgent suspected cancer route (40.4% v 38.9%) 
although these differences were not statistically significant (table 2).  
Alarm symptoms at presentation 
There were no significant differences in presentation of alarm symptoms by cancer type at 
first consultation irrespective of locality, apart from urban patients with testicular or penile 
cancer (P=0.013), though numbers were very low (n=44). Across all cancers, rural patients 
were significantly more likely to have at least one alarm feature at presentation (P=0.044) 
(table 3).  
Symptoms and signs, pre-referral consultations, and avoidable delay 
No significant difference was found between urban and rural-dwellers in the number of 
symptoms at presentation, or in the number of positive signs and tests at presentation. 
However, rural patients had significantly more consultations before referral than urban 
patients (Median (IQR) 1, 1-3: P=0.016), and were also significantly more likely to have three 
or more consultations before referral (P= 0.002), (table 4).  
A significantly higher proportion of rural patients (32.3% v 26.4%) were judged by their GP to 
have experienced an avoidable delay in their diagnostic journey compared with urban 
patients (P=0.001), and rural GPs were more likely to perceive that the avoidable delay had 
occurred in primary care. Rural GPs were also more likely to consider their own pre-referral 
clinical appraisal had been the source of the avoidable delay, and less likely to consider that 
the patient was responsible for delayed help-seeking (P=0.006), (table 4). 
GP initiated investigations 
Rural patients were significantly more likely to have investigations instigated by their GP at 
their first relevant consultation than urban patients (P=0.029), with rural GPs significantly 
more likely to initiate blood tests at this consultation than their urban counterparts (P<0.001), 
(table 5). 
Key cancer diagnostic intervals 
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Median primary care interval was four days for urban patients (IQR 4, 0-22) and seven days 
for rural patients (IQR 7, 0-30) but this difference was not significant (p=0.181). Also, the odds 
of a prolonged primary care interval (longer than 60 days or longer than 90 days) were not 
significantly higher in rural patients in either unadjusted or adjusted analyses (table 6). 
Median diagnostic interval was significantly longer (5 days) for rural patients (P=0.039), but 
rural patients were no more likely to have a prolonged diagnostic delay in the adjusted 
analysis (> 60 days (OR 0.821, CI.0.616-1.094)) and (> 90 days (OR 0.807, CI 0.581-1.122)), 
table 6. 
There were no significant differences in treatment or secondary care interval between rural 
and urban patients. 
 
4. DISCUSSION 
Summary of key findings 
Routes to diagnosis of rural and urban patients were similar. Rural patients were more likely 
to have alarm features of potential cancer at presentation, were seen more often before being 
referred, and were more likely to have blood tests ordered by their GP. Rural GPs were more 
likely to perceive that they had caused avoidable delays for their rural patients, and less likely 
to perceive that their patients had delayed in help-seeking. Despite this, rural patients were 
no more likely to have significantly longer cancer diagnostic intervals. The trend to slightly 
longer median primary care and diagnostic intervals observed in rural patients may reflect 
rural GPs being more likely to investigate before referral.  
 
Comparison with other literature 
In the systematic review by Carriere et al (2018) potential mechanistic explanations were 
included in a socio-ecological model comprising levels of culture and community; wider 
policy; healthcare institutions and patient factors. At the patient level, in the current study 
we found rural patients had more alarm features at presentation, consistent with an earlier 
study in Northeast Scotland where colorectal cancer patients were more likely to have alarm 
symptoms at presentation (Murage et al, 2018). 
Research using large patient samples and based on cancer registry data have found rural 
patients are less likely to be referred urgently, more likely to be diagnosed as an emergency 
or at post-mortem, and more likely to have a screen-detected cancer (Campbell et al, 2000; 
Murage et al, 2019; Leung et al, 2015). In contrast, this study found no significant difference 
in the routes to diagnosis experienced by rural and urban patients, although the sample was 
gathered in a different way. Our findings are supported in part by two Danish studies. The first, a 
national cohort study of 37,872 patients looking at cancer delays and travel distance to health 
services, found travel distance from a patient’s home to their GP was not associated with time 
intervals in the diagnostic journey, but was associated with increased travel distance to the 
hospital (Virgilsen, Møller, and Vedsted, 2019a). The second study, looking at cancer 
diagnostic facilities and cancer stage for 12 different cancers (n=256,663 patients), found no 
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pronounced associations between travel distance to the GP and tumour stage. However, for 
the easy-to-diagnose cancer types (rectum cancer, malignant melanoma, testis cancer and 
cervix) a longer travel distance to the hospital was associated with advanced disease while it 
lessened the odds for the hard-to-diagnose cancer types (stomach, pancreatic, lung and 
ovarian cancer) (Virgilsen, Møller, and Vedsted, 2019b). 
Previous investigators have cited poorer access to investigations and specialist care as a 
potential cause of poorer rural cancer outcomes (Jones et al, 2010; Barisic 2016). A recent 
large English study also reported that rural patients were less likely to be referred using urgent 
suspected cancer pathways (Murage et al, 2019). GPs are influenced by context in their 
decision-making, and could conceivably factor in travel and cost burdens when deciding how 
to manage patients who might have cancer (Sladden, 1998; Bentham, 1982; Kostopolou, 
2019).  Our finding that rural patients were seen more often prior to referral, and were more 
likely to have blood-tests initiated by their GP is interesting in this context. It is consistent 
with a pan-European study that found rural GPs were just as likely to take diagnostic action 
at the initial consultation, but that the action taken may be considered in light of the travel 
and cost burden to the patient (Murchie et al, 2020). Rural GPs were also more likely to 
perform blood tests at the index consultation, and as the overall primary care delay is not 
significantly different,  it is possible that rural GPs, mindful of the implications for their 
patients, are simply establishing greater certitude that referral is completely necessary. This 
action by rural GPs could also partly explain why alarm features at presentation (which 
included positive tests) were more likely for rural than urban patients. As in this study, in 
geographically similar New Zealand, rates of referral to secondary care by rural and urban GPs 
were similar (Hider et al, 2000). 
A previous study in Northeast Scotland found that patients living furthest from hospitals 
actually had significantly shorter time to treatment for cancer (Turner et al, 2017). Together 
with the current results it does not appear that rural-dwelling cancer patients in Scotland are 
disadvantaged by longer diagnostic delays in primary care compared with those living in cities. 
Relevant also is a randomized trial in rural Western Australia where neither a community nor 
GP educational intervention succeeded in reducing total diagnostic cancer intervals (Emery 
et al, 2017). It could be that rural patients do not suffer prolonged delays in the diagnosis of 
their cancer, and that there is little scope to reduce delays relative to urban-dwellers any 
further. 
Strikingly, rural GPs were significantly more likely to perceive that they, and not their patient, 
had delayed diagnosis in an avoidable way. This view is not supported by the objective data, 
so speculatively it may represent differences in the attitudes of rural GPs and the relationship 
they have with their patients. A recent focus group study concluded that rural German GPs 
formed closer relationships and felt greater responsibility for their patients (Pohontsch et al, 





Strengths and limitations 
This study is based on a large sample of patients from throughout Scotland diagnosed with a 
new primary cancer. The sample is representative of Scottish cancer patients with respect to 
gender, age and cancer site and key demographics and, for the purpose of this study, a good 
proportion of rural patients. Participating general practitioners have provided rich, granular 
and detailed information, giving a detailed narrative picture of each patients’ diagnosis – 
information that is only available directly from patient records. This also enables access to 
variables which in previous rural vs urban cancer diagnosis research have only been 
speculated about. The study was also able to use the Scottish Government’s Urban Rural 
classifications which categorize patients based on geographical factors likely to influence 
healthcare access and health outcomes. We have added further definition by presenting data 
using both the 2-fold and 6-fold classifications. 
NCDA data was collected GPs or practice staff direct from their own patents’ practice-held 
records. There is, therefore, the possibility of bias in data-entry particularly where the pre-
diagnostic pathway was complex. On the other hand, the audit team allocated cases to 
practices for data extraction minimising the potential bias from self-selection of cases. 
Furthermore, most of the data gathered related to objective facts collected onto a structured 
data-collection proforma. To obtain a complete picture of cancer diagnosis in Scotland NCDA 
collected data about a heterogenous group of cancers which have different natural histories 
and can present in different ways which creates some challenges to interpreting the data. To 
mitigate this issue we have included cancer site as a potential confounder in the multivariable 
analysis of prolonged diagnostic intervals. The data are from 2014 and local health services 
continue to evolve. However, there have been no major changes in cancer diagnostics or rural 
healthcare delivery in Scotland that would make the situation any different now. Data is not 
available on patients’ journeys prior to presenting to their GP. This is difficult to collect, but is 
an important consideration for future research since it is conceivable that geography could 
have a considerable impact on this. Rurality in Scotland differs considerably from elsewhere 
in the UK and the world, meaning the results may not be generalizable. On the other hand, 
Scotland has similar rural cancer inequity to elsewhere, so the current research represents a 
good starting point for researchers wishing to conduct similar or comparative research.  
 
Implications for future research 
Our data suggest rural patients may tend to be more symptomatic when presenting to their 
GPs and then experience their cancer diagnosis differently. Detailed research exploring the 
impact of geography on patient behaviour and decision-making when faced with potential 
cancer symptoms should follow. 
Rural patients had similar routes to diagnosis as urban patients, were not diagnosed at a later 
stage and where key pathway delays were longer it was by a few days, which seems highly 
unlikely to have been clinically significant. From an international perspective, these data are 
incremental, adding definition to the socio-ecological model, and suggesting similar methods 
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should be replicated to explore geographical influences on primary care cancer diagnosis 
internationally.  
Overall, and from a Scottish perspective, the current results are consistent with the NASCAR 
study, conducted in the Northeast of Scotland (Turner et al, 2017). They suggest that rurality 
in Scotland does not lead to later stage diagnosis, delayed diagnosis or delayed treatment. 
This suggests that future research might focus on pre-presentational and post-treatment 




In a descriptive analysis of Scottish Cancer diagnoses from 2014 rural patients may have 
experienced primary care differently in the lead-up to a cancer diagnosis. Against a 
background of greater cost and travel burden, rural patients appeared more symptomatic at 
presentation, and then in likely collaboration with rural GPs, were more likely to have blood 
tests and review appointments to establish the basis for referral. Contrary to objective 
evidence, rural GPs appeared more likely to judge themselves rather than patients to have 
avoidably delayed the cancer diagnosis. This suggests that rural GPs may have different 
attitudes and more trusting relationships with their patients than urban counterparts. 
Together, these observations raise important research questions about geographical 
influences on patient and GP behaviour which could be explored using enhanced datasets, 
questionnaires and qualitative research methods. 
Overall, however time to diagnosis and treatment for rural patients was not significantly 
prolonged compared to city-dwellers. These data add to evidence suggesting that poorer rural 
cancer outcomes in Scotland are not caused by prolonged diagnostic pathways in primary 
care. Future research must therefore explore geographical influences on the entirety of the 
cancer journey, from symptom development and appraisal to survivorship care, if the root 
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TABLE 1: SAMPLE COMPOSITION BY SCOTTISH URBAN RURAL 2-FOLD CLASSIFICATION (n=1905) 
  TOTAL SCOTTISH CASES 20141 TOTAL OF NCDA n(%) Urban Areas N=1538 n(%) Rural Areas N=476 n(%) 
      
      
GENDER MALE 15,528 (49.0) 973 (51.1) 732 (50.3) 241 (53.6) 
 FEMALE 16,183 (51.0) 932 (48.9) 723 (49.7) 209 (46.4) 
AGE GROUP (YEARS) 0-24 524 (1.7) 17 (0.9) 11 (0.8) 6 (1.3) 
 25-49 2,746 (8.6) 175 (9.2) 139 (9.6) 36 (8.0) 
 50-64 7,966 (25.1) 468 (24.6) 359 (24.7) 109 (24.2) 
 65-74 9,492 (29.9) 528 (27.7) 396 (27.2) 132 (29.3) 
 75-84 7,940 (25.0) 510 (26.8) 390 (26.8) 120 (26.7) 
 >84 3,043 (9.6) 207 (10.9) 160 (11.0) 47 (10.4) 
SIMD Category (based on quintiles)2 1 (Most Deprived) 29,458 (18.1) 441 (23.1) 400 (27.5) 41 (9.1) 
 2 31,208 (19.2) 351 (18.4) 297 (20.4) 54 (12.0) 
 3 33,241 (20.4) 323 (17.0) 211 (14.5) 112 (24.9) 
 4 34,590 21.3) 431 (22.6) 236 (16.2) 195 (43.3) 
 5 (Least Deprived) 33,939 (20.9) 359 (18.8) 311 (21.4) 48 (10.7) 
CANCER SITE Bladder 841 (2.7) 50 (2.6) 39 (2.7) 11 (2.4) 
 Brain 443 (1.4) 23 (1.2) 16 (1.1) 7 (1.6) 
 Breast 4,610 (14.5) 209 (11.0) 155 (10.7) 54 (12.0) 
 Cancer of Unknown Primary3 Not available 29 (1.5) 18 (1.2) 11 (2.4) 
 Colon 2,586 (8.2) 158 (8.3) 121 (8.3) 37 (8.2) 
 Leukaemia 584 (1.8) 44 (2.3) 30 (2.1) 14 (3.1) 
 Liver 572 (1.8) 56 (2.9) 47 (3.2) 9 (2.0) 
 Lung 5,307 (16.7) 359 (18.8) 291 (20.0) 68 (15.1) 
 Lymphoma 1,177 (3.7) 78 (4.1) 57 (3.9) 21 (4.7) 
 Melanoma 1,248 (3.9) 79 (4.1) 62 (4.3) 17 (3.8) 
 Multiple Myeloma 435 (1.4) 21 (1.1) 16 (1.1) 5 (1.1) 
 Oesophageal 932 (2.9) 63 (3.3) 49 (3.4) 14 (3.1) 
 Oral 896 (2.8) 51 (2.7) 40 (2.7) 11 (2.4) 
 Other 2,909 (9.1) 96 (5.0) 80 (5.5) 16 (3.6) 
 Other Gynae 1,767 (5.6) 75 (3.9) 54 (3.7) 21 (4.7) 
 Ovarian 595 (1.9) 38 (2.0) 28 (1.9) 10 (2.2) 
 Pancreatic 793 (2.5) 55 (2.9) 41 (2.8) 14 (3.1) 
 Prostate 3,202 (10.1) 222 (11.7) 160 (11.0) 62 (13.8) 
 Rectal 1,135 (3.6) 73 (3.8) 58 (4.0) 15 (3.3) 
 Renal 1,006 (3.2) 71 (3.7) 50 (3.4) 21 (4.7) 
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 Stomach 673 (2.1) 55 (2.9) 43 (3.0) 12 (2.7) 
CANCER STAGE3 1 Not available 207 (10.9) 164 (11.3) 43 (9.6) 
 2 Not available 238 (12.5) 175 (12.0) 63 (14.0) 
 3 Not available 237 (12.4) 173 (11.9) 64 (14.2) 
 4 Not available 416 (21.8) 321 (22.2) 95 (21.1) 
 Unknown Not available 807 (42.4) 622 (42.7) 185 (41.1) 
COMORBIDITIES3 None Not available 475 (24.9) 373 (25.8) 102 (22.7) 
 One Not available 537 (28.2) 407 (28.2) 130 (29.0) 
 Two  Not available 469 (24.6) 350 (24.3) 119 (26.5) 
 Three or more Not available 411 (21.6) 313 (21.7) 98 (21.8) 
 Unknown Not available 13 (0.7) n<10 n<10 
1 Data on all Scottish cancer cases 2014 obtained from ISD Scotland. Cancer Incidence in Scotland Dashboard. https://www.isdscotland.org/Health-
Topics/Cancer/Publications/2019-04-30/visualisation.asp 
2SIMD Category totals and percentages relate to the period 2013-2017 combined. ISD does not publish deprivation data for individual years 







TABLE 2: METHOD OF FIRST DETECTION AND TYPE OF REFERRAL BY URBAN RURAL 2 FOLD CLASSIFICATION (n=1905) 














TOTAL 1905 (100)       




       
Urban 1455 (100) 1333 (91.6) 113 (7.8) n≤5 n≤5 n≤5 n≤5 
Rural 450 (100) 417 (92.7) 31 (6.9) n≤5 n≤5 n≤5 n≤5 
      P=0.3601  
        
 TOTAL OF NCDA n(%) Routine 
n(%) 












TOTAL 1905 (100)       




       
Urban 1455 (76.4) 162 (11.1) 128 (8.8) 566 (38.9) 313 (21.5) 130 (8.9) 124 (8.5)88(5.7) 
Rural 450 (23.6) 42 (9.3) 54 (12.0) 182 (40.4) 89 (19.8) 37 (8.2) 34 (7.6)31(6.5) 
       
 P=0.4451 
 
1  Pearson’s Chi-Squared Test
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TABLE 3: PRESENCE OF AT LEAST ONE SCOTTISH REFERRAL GUIDELINE ALARM FEATURES AT PRESENTATION BY INDIVIDUAL SITE GUIDELINE 2-FOLD 
URBAN RURAL CLASSIFCATION (n=1905) 
  Urban Areas (N=1455) 
n(%) 




P Value (Chi-Squared 
test)1 
At Least One Alarm Feature Present* Yes 1119 (77.0) 367 (81.5) 1486 (78.0)  
 No 336 (23.0) 83 (18.4) 419 (22.0) P=0.044 
1 Chi-squared test continuity correction 







TABLE 4: SYMPTOMS AND SIGNS AT PRESENTATION (n=1905), NUMBER OF PRE-REFERRAL CONSULTATIONS (n=1905) AND AVOIDABLE DELAYS (n=1669 – 
excluding 236 unknowns) BY 2-FOLD URBAN RURAL CLASSIFICATION 





Number of symptoms at presentation Median (IQR) 1.0(1-2) 1.0(1-3)  
    P=0.1401 
Number of positive signs or tests at presentation Median (IQR) 0(0-1) 0(0-1)  
    P=0.3261 
Median number of consultations before referral Media (IQR) 1.0(1-2) 1.0(1-3)  
    P=0.0161 
Three or more consultations before referral Yes n(%) 286(19.7) 122(27.1)  
 No n(%)  1024(70.4) 293(65.1)  
 Unknown n(%) 145(10.0) 35(7.8) P=0.0022 
     







Avoidable Delay in Diagnostic Journey  Yes 348 (23.9) 137 (30.4) 485 
 No 982 (73.6) 296 (67.7) 1184 
    P=0.0013 
Where Avoidable Delay Occurred Pre-consultation 69 (19.8) 19(13.4) 89 
 Primary Care 132 (38.0) 61(43.2) 195 
 Secondary or Tertiary 
Care 
136 (39.2) 57 (40.4) 193 
 Not known n<10 n<10 16 
    P=0.0582 
     
Stage of Journey Delayed Help-seeking 78 (36.1) 23 (16.8) 101 
 Clinical appraisal 39 (18.5) 30 (21.9) 69 
 Investigation 91 (26.1) 33 (24.1) 124 
 Investigation 
Reporting 
28 (8.0) n<10 36 
 Referral 55 (15.8) 19 (13.9) 74 
 Appointment 23 (6.6) n<10 30 
 Follow-up of 
Abnormal Result 
26 (7.5) 11 (8.0) 37 
 Not Known n<10 n<10 14 
     
    P=0.0062 
1 Mann Whitney U Test 







TABLE 5: GP INITIATIED INVESTIGATIONS BY 2-FOLD URBAN RURAL CLASSIFICATION (n=1846 excluding 59 unknowns. 120 inapplicable cases included as 
“no.”) 





GP Led Investigation Occurred  YES 728 (51.7) 185 (42.1) 982 
 NO  679 (48.3) 254 (57.9) 864 
    P=0.029 1 
GP Initiated Blood Tests YES 499 (35.5) 199 (45.3) 698 
 NO  908 (64.5) 240 (54.7) 1148 
    P<0.0011 
GP Initiated Urine Tests YES 39 (2.1) 9 (2.1) 38 
 NO 1378 (97.9) 430 (97.9) 1808 
    P=1.0001 
GP Initiated Imaging YES 290 (20.6) 100 (22.8) 390 
 NO 1117 (79.4) 339 (77.2) 1456 
    P=0.3661 
GP Initiated Endoscopy YES 44 (3.1) 11 (2.5) 55 
 NO 1363 (96.9) 428 (97.5) 1791 
    P=0.6121 
GP Initiated Other Tests YES 48 (3.4) 23 (5.2) 71 
 NO 1359 (96.6) 416 (94.8) 1775 
    P=0.1101 






































**Adjusted Odds Ratio (CI) 
   Urban Rural  Urban Rural Urban Rural 
Primary Care Interval N=987* N=327*        
  Median interval days   4(0-22) 7(0-30) P=0.1811     
   > 60 days yes 105(10.6) 43(13.1)   P=0.2532 1 0.786(0.538-1.149) 1 0.837(0.550-1.273) 
   > 90 days yes 70(7.1) 31(9.5)   P=0.1992 1 0.729(0.468-1.135) 1 0.650(0.395-1.070) 
          
Diagnostic Interval N=1191* N=381*        
  Median interval days   29.0(13-66) 34.0(14-75) P=0.0391     
   > 60 days yes 326(27.4) 119(31.2)   P=0.1642 1 0.830(0.645-1.067) 1 0.821(0.616-1.094) 
   > 90 days yes 203(17.0) 77(20.2)   P=0.1842 1 0.811(0.606-1.086) 1 0.807(0.581-1.122) 
          
Secondary Care Interval N=735* N=242*        
Median interval days   62(36-106) 62(34-105) P=0.9381     
   > 60 days yes 375(51.0) 124(51.2)   P=1.0002 1 0.991(0.741-1.326) 1 1.064(0.753-1.503) 
   > 90 days yes 235(32.0) 235(32.0)   P=0.4782 1 0.884(0.651-1.201) 1 0.971(0.671-1.406) 
          
Treatment Interval N=932* N=291*        
 Median interval days   39.5(20-69) 37.0(17-66) P=0.3501     
   > 60 days yes 275(29.5) 82(28.2)   P=0.7182 1 1.067(0.797-1.428) 1 0.993(0.705-1.400) 
   > 90 days yes 155 (16.6) 41 (14.1)   P=0.3472 1 1.216(0.838-1.765) 1 1.130(0.731-1.746) 
          
1 Mann Whitney U Test 
2 Chi-Squared Test Continuity Correction 
*Intervals are restricted to 0-730 days and any intervals out with this range are excluded to minimise data errors. Patients with a cancer diagnosed through screening 
(n=109) are also excluded. Additionally, where relevant valid dates are not available intervals could not be calculated. 




Figure 1: Scottish Government Urban Rural Classification 2-fold and 6-fold breakdowns 
Scottish Government 2-fold Urban Rural Classification 
1 Urban Area Settlements of 3,000 or more people 
2 Rural Area Areas with a population of less than 3,000 people 
 
Scottish Government 6-fold Urban Rural Classification 
1 Large Urban Area Settlements of 125,000 or more people 
2 Other Urban Area Settlements of 10,000 to 124,999 people. 
3 Accessible Small Towns Settlements of 3,000 to 9,999 people and within a 30 minute drive of a settlement of 10,000 or more 
4 Remote Small Towns Settlements of 3,000 to 9,999 people and with a drive time of over 30 minutes to a settlement of 10,000 or 
more 
5 Accessible Rural Areas with a population of less than 3,000 people, and within a 30 minute drive time of a settlement of 10,000 
or more 
6 Remote Rural Areas with a population of less than 3,000 people, and with a drive time of over 30 minutes to a settlement of 
10,000 or more 
 
Adapted from: Scottish Government. Scottish Government Urban Rural Classification. 





Appendix I (Sample NCDA data collection form – attached Excel file) 
Appendix II (Analysis by Scottish Urban Rural 6 Fold Classification) 
Supplementary TABLE S1: SAMPLE COMPOSITION BY SCOTTISH URBAN RURAL 6-FOLD CLASSIFICATION (n=2014) 
 TOTAL OF NCDA n(%) Large Urban Areas 
N=780 
n(%) 
Other Urban Areas 
N=474 
n(%) 
Accessible Small Towns 
N=207 
n(%) 
Remote Small Towns 
N=77 
n(%) 
Accessible Rural Areas 
N=224 
n(%) 
Remote Rural Areas 
N=252 
n(%) 
TOTAL 1905       
        
GENDER        
MALE 973 (51.1) 377 (50.8) 215 (48.2) 101 (52.1) 39 (53.4) 105 (49.1) 136 (57.6) 
FEMALE 932 (48.9) 365 (49.2) 231 (51.8) 93 (47.9) 34 (46.6) 109 (50.9) 100 (42.4) 
        
AGE GROUP (YEARS)        
0-24 17 (0.8) 8 (1.0) 0(0) n<10  n<10 n<10 n<10 
25-49 175 (9.2) 78 (10.5) 38 (8.5) 18 (9.3) n<10 21 (9.8) 15 (6.4) 
50-64 468 (24.6) 194 (26.1) 111 (24.9) 45 (23.2) n<10 53 (24.8) 56 (23.7) 
65-74 528 (27.7) 190 (25.6) 128 (28.7) 52 (26.8) 26 (35.6) 66 (30.8) 66 (28.0) 
75-84 510 (26.8) 196 (26.4) 117 (26.2) 57 (29.4) 20 (27.4) 53 (24.8) 67 (28.4) 
>84 207 (10.9) 76 (10.2) 52 (11.7) 20 (10.3) 12 (16.4) 20 (9.3) 27 (11.4) 
        
SIMD        
1 (Most Deprived) 441 (23.1) 292 (39.4) 96 (21.5) 13(6.3) n<10 24 (11.2) 17 (7.2) 
2 351 (18.4)  117 (15.8) 124 (27.8) 45(21.8) 14 (19.2) 26 (12.1) 28 (11.9) 
3 323 (17.0) 75 (10.1) 60 (13.5) 45(21.8) 35 (47.9) 37 (17.3) 75 (31.8) 
4 431 (22.6)  89 (12.0) 87 (19.5) 55(26.6) n<10 98 (45.8) 97 (41.1) 
5 (Least Deprived) 359 (18.8)  169 (21.8) 79 (17.7) 49(23.7) 16 (21.9) 29 (13.6) 19 (8.1) 
        
CANCER SITE        
Bladder 50 (2.5) 22 (3.0) 11 (2.5) n<10 n<10 n<10 n<10 
Brain 23 (1.2) n<10 n<10 n<10 n<10 n<10 n<10 
Breast 209 (11.0) 73 (9.8) 48 (10.8) 28 (14.4) n<10 33 (15.4) 21 (8.9) 
Cancer of Unknown 
Primary 
29 (1.5) n<10 11(2.3) n<10 n<10 n<10 n<10 
Colon 158 (8.3) 59 (8.0) 34 (7.6) 23 (11.9) n<10 15 (7.0) 22 (9.3) 
Leukaemia 44 (2.3) 17 (2.3) n<10 n<10 n<10 n<10 11 (2.3) 
Liver 56 (2.9)  26 (3.5) 18 (4.0) n<10 n<10 n<10 n<10 
Lung 359 (18.8) 165 (22.2) 87 (19.5) 25 (12.9) 14 (19.2) 31 (14.5) 37 (15.7) 
Lymphoma 78 (4.1) 30 (4.0) 19 (4.3) n<10 n<10 10 (4.7) 11 (4.7) 
Melanoma 79 (4.1) 24 (3.2) 23 (5.2) 12 (6.2) n<10 n<10 12 (5.1) 
Multiple Myeloma 21 (1.1) 12(1.6) n<10 n<10 n<10 n<10 n<10 
Oesophageal 63 (3.3) 30 (4.0) 13 (2.9) n<10 n<10 n<10 n<10 
Oral 51 (2.7) 25 (3.4) 10 (2.2) n<10 n<10 n<10 n<10 
Other 96 (5.0) 39 (5.3) 29 (6.5) n<10 n<10 n<10 n<10 
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Other Gynae 75 (3.9)  25 (3.4) 21 (4.7) n<10 n<10 n<10 12 (5.1) 
        
CANCER STAGE3        
1 207 (10.9) 93 (12.5) 42 (9.4) 21 (10.8) n<10 21 (9.8) 22 (9.3) 
2 238 (12.5) 82 (11.1) 50 (11.2) 35 (18.0) n<10 36 (16.8) 27 (11.4) 
3 237 (12.4) 90 (12.1) 46 (10.3) 24 (12.4) 13 (17.8) 30 (14.0) 34 (14.4) 
4 416 (21.8) 166 (22.4) 99 (22.2) 42 (21.6) 14 (19.2) 50 (23.4) 45 (19.1) 
Unknown 807 (42.4) 311 (41.9) 209 (46.9) 72 (37.1) 30 (41.1) 77 (36.) 108 (45.8) 
        
COMORBIDITIES3        
None 475 (25.1) 178 (24.2) 125 (28.2) 56 (29.2) 14 (19.4) 53 (24.9) 49 (20.8) 
One 537 (28.4) 200 (27.2) 130 (29.3) 52 (27.1) 25 (34.7) 66 (31.0) 64 (27.1) 
Two  469 (24.8) 178 (24.2) 110 (24.8) 43 (22.4) 19 (26.4) 51 (23.9) 68 (28.8) 
Three or more 411 (21.7) 180 (24.5) 78 (17.6) 41 (21.4) 14 (19.4) 43 (20.2) 55 (23.3) 
Unknown 13 (0.7) n<10 n<10 n<10 n<10 n<10 n<10 
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Supplementary TABLE S2: METHOD OF FIRST DETECTION BY URBAN RURAL 6-FOLD CLASSIFICATION (n=1905) 













TOTAL 1905       




       
Large Urban Area 742 677 (91.2) 60 (8.1) n<10 n<10 n<10 n<10 
Other Urban Area 446 410 (91.9) 33 (7.4) n<10 n<10 n<10 n<10 
Accessible Small 
Town 
194 179 (92.3) 15 (7.7) n<10 n<10 n<10 n<10 
Remote Small Town   73 67 (91.8) n<10 n<10 n<10 n<10 n<10 
Accessible Rural Area 214 196 (91.6) 17 (7.9) n<10 n<10 n<10 n<10 
Remote Rural Area 236 221 (93.6) 14 (5.9) n<10 n<10 n<10 n<10 
       P=0.570 
1 Pearson Chi-squared test 
 
Supplementary TABLE S3: TYPE OF REFERRAL BY URBAN RURAL 6-FOLD CLASSIFICATION (n=1905) 
 TOTAL OF NCDA n Routine 
n(%) 












TOTAL 1905       




       
Large Urban Area 742 96 (12.9) 67 (9.0) 271 (36.5) 177 (23.9) 61 (8.2) 62 (8.4) 
Other Urban Area 446 46 (10.3) 38 (8.5) 171 (38.3) 98 (22.0) 50 (11.2) 39 (8.7) 
Accessible Small 
Town 
194 12 (6.2) 19 (9.8) 96 (49.5) 29 (14.9) 21 (10.8) 14 (7.2) 
Remote Small Town 73 8 (11.0) n<10 28 (38.4) 9 (12.3) 15 (20.5) 9 (12.3) 
Accessible Rural Area 214 18 (8.4) 27 (12.6) 80 (37.4) 46 (21.5) 24 (11.2) 17 (7.9) 
Remote Rural Area 236 24 (10.2) 27 (11.4) 102 (43.2) 43 (18.2) 18 (7.6) 17 (7.2) 
       P=0.0011 






Supplementary TABLE S4: PRESENCE OF AT LEAST ONE SCOTTISH REFERRAL GUIDELINE ALARM FEATURES AT PRESENTATION BY 6-FOLD URBAN RURAL 
CLASSIFCATION (n=1905) 
  Large Urban Areas 
n(%) 














At Least One Alarm Feature Yes 575(38.7) 348(23.4) 147(9.9) 49(3.3) 175(11.8) 192(12.9) 1486 
 No 167(39.9) 98(23.4) 47(11.2) 24(5.7) 39(9.3) 44(10.5) 419 
        P=0.1081 




Supplementary TABLE S5: NUMBER OF SYMPTOMS AND SIGNS AT PRESENTATION BY 6-FOLD URBAN RURAL CLASSIFCATION (n=1905) 
 Large Urban Areas 
n(%) 
Other Urban Areas 
 n(%) 
 Accessible Small Towns 
n(%) 
Remote Small Towns 
n(%) 
Accessible Rural Areas 
n(%) 
Remote Rural Areas 
n(%) 
Median Symptoms at presentation (IQR)  1(1-2) 1(1-2) 1(1-2) 1(0-2.5) 1(1-3) 1(1-2) 
      P=0.4671 
Median Positive Signs or Tests at Presentation (IQR) 0(0-1) 0(0-1) 0(0-1) 0(0-1) 1(0-1) 0(0-1) 
      P=0.3791 
       
1 Kruskall Wallis Test
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Supplementary TABLE S6: AVOIDABLE DELAYS BY 6-FOLD URBAN RURAL CLASSIFCATION (n=1669, excluding 236 unknowns) 
  Large Urban Areas 
N=677 
n (%) 
Other Urban Areas 
N=407 
n (%) 
















Delay in Diagnostic 
Journey  
YES 188 (27.8) 81 (19.9) 59 (31.4) 20 (34.5) 57 (27.0) 80 (36.0) 485 
 NO 489 (72.2) 326 (80.1) 129 (68.6) 38 (65.5) 154 (73.0) 142 (64.0) 1278 
       P<0.0011  
Where Delay Occurred Pre-consultation 49 (26.1) 9 (11.1) 8 (13.6) n<10 n<10 11 (13.8) 88 
 Primary Care 64 (34.0) 37 (45.7) 25 (42.4) n<10 29 (50.9.7) 32 (40.0) 193 
 Secondary or Tertiary 
Care 
70 (37.2) 29 (35.8) 26 (44.1) 10 (50.0) 20 (35.1) 33 (41.3) 188 
 Not known n<10 n<10 n<10 n<10 0 (0) n<10 16 
       P<0.0351  
Stage of Journey 
Delayed 
Help-seeking 51 (27.1) 11 (13.6) 11 (18.6) n<10 n<10 15 (18.8) 101 
 Clinical appraisal 22 (11.7) n<10 n<10 0 (0) 13 (22.8) 17 (21.3) 69 
 Investigation 40 (21.3) 24 (29.6) 21 (35.6) n<10 16 (28.1) 17 (21.3) 124 
 Investigation Reporting 14 (7.4) n<10 n<10 n<10 n<10 n<10 36 
 Referral 27 (14.4) 19 (23.5) n<10 n<10 n<10 11 (13.8.0) 74 
 Appointment 13 (6.9) n<10 n<10 n<10 n<10 n<10 30 
 Delayed result follow-up 16 (8.5) n<10 n<10 n<10 n<10 n<10 37 
 Not known n<10 n<10 n<10 n<10 n<10 n<10 14 
       P=0.2291  
1 Pearson’s Chi-squared test 
 
Supplementary TABLE S7: GP INITIATIED INVESTIGATIONS BY 6-FOLD URBAN RURAL CLASSIFCATION (n=1860, excluding 45 unknowns) 
  Large Urban Areas 
n (%) 
Other Urban Areas 
 n (%) 
 Accessible Small 
Towns 
n (%) 





Remote Rural Areas 
 n (%) 
TOTAL 
GP Led Investigation 
Occurred  
YES 362 (50.3) 201 (46.4) 87 (44.6) 29 (40.8) 90 (43.4) 95 (40.6) 864 
 NO 357 (49.7) 232 (53.6) 108 (55.4) 42 (59.2) 118 (56.7) 139 (59.4) 996 
       P=0.0871  
GP Initiated Blood Tests YES 246 (34.2) 157 (36.3) 69 (35.4) 32 (45.1) 92 (44.2) 108 (46.2) 704 
 NO 473 (65.8) 276 (63.7) 126 (64.6) 39 (54.9) 116 (55.8) 141 (53.8) 1156 
       P=0.0041  
GP Initiated Urine Tests YES 19 (2.6) n<10 n<10 n<10 n<10 n<10 40 
 NO 700 (97.4) 428 (98.8) 190 (97.4) 70 (98.6) 204 (98.1) 228 (97.4) 1820 
       P=0.6301  
GP Initiated Imaging YES 139 (19.3) 103 (23.8) 33 (16.9) 15 (21.1) 47 (22.6) 54 (23.1) 391 
 NO 580 (80.7) 330 (76.2) 162 (83.1) 56 (78.9) 161 (77.4) 180 (76.9) 1469 
       P=0.2961  
GP Initiated Endoscopy YES 24 (3.3) 16 (3.7) n<10 n<10 n<10 n<10 60 
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 NO 695 (96.7) 417 (96.3) 191 (97.9) 69 (97.2) 201 (96.6) 227 (97.0) 1800 
       P=0.9361  
GP Initiated Other Tests YES 16 (2.2) 18 (4.2) 12 (6.2) n<10 n<10 18 (7.7) 74 
 NO 703 (97.8) 415 (95.8) 194 (93.8) 66 (93.0) 203 (97.6) 216 (92.3) 1786 
       P=0.0011  






Supplementary TABLE S8: NUMBER OF PRE-REFERRAL CONSULTATIONS BY 6-FOLD URBAN RURAL CLASSIFCATION (n=1905) 
  Large Urban Areas 
N=742 
n(%) 
Other Urban Areas 
N=446 
 n(%) 












Remote Rural Areas 
N=236 
n(%) 
MEDIAN NUMBER OF CONSULTATIONS BEFORE 
REFERRAL  
Median (IQR) 1(1-2) 1(1-2) 1(1-3) 2(1-2) 1(1-3) 20(1-3) 
       P=0.1081 
THREE OR MORE CONSULTATION BEFORE REFERRAL YES 136(18.3) 86(19.3) 53(27.3) 11(15.1) 52(24.3) 70(29.7) 
 NO 528(71.2) 317(71.1) 133(68.6) 46(63.0) 146(68.2) 147(62.3) 
 UNKNOWN 78(10.5) 43(9.6) 8(4.1) 16(21.9) 16(7.5) 19(8.1) 
       P=0.0042 
1 Kruskall Wallis test 
2 Pearson’s Chi-squared test 
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Supplementary TABLE S9: PRIMARY CARE INTERVAL BY 6-FOLD URBAN RURAL CLASSIFCATION (n=1314)* 




Other Urban Areas 
N=291* 
 n(%) 
 Accessible Small Towns 
N=146* 
n(%) 
Remote Small Towns 
N=46* 
n(%) 
Accessible Rural Areas 
N=157* 
n(%) 
Remote Rural Areas 
N=170* 
n(%) 
PRIMARY CARE INTERVAL (IQR) MEDIAN (IQR) 3(0-21) 4(0-20) 8(0.75-32.25) 5.5(0.75-24) 7(0-24) 7(0-33.25) 
       P=0.1631 
PRIMARY CARE INTERVAL > 60 DAYS YES 55(10.9) 27(9.3) 18(12.3) 5(10.9) 15(9.6) 28(16.5) 
 NO 449(89.1) 264(90.7) 128(87.7) 41(89.1) 142(90.4) 142(83.5) 
       P=0.2652 
PRIMARY CARE INTERVAL > 90 DAYS YES 42(8.3) 14(4.8) 12(8.2) n<5 n<5 20(11.8) 
 NO 462(91.7) 277(95.2) 134(91.8) 44(95.7) 146(93.0) 150(88.2) 
       P=0.1282 
UNADJUSTED ODDS OF PCI > 60 DAYS OR (95% Cis) 1 1.185(0.735-1.911) 0.813(0.466-1.418) 1.038(0.395-2.729) 1.151(0.632-2.096) 0.616(0.379-1.000) 
        
UNADJUSTED ODDS OF PCI > 90 DAYS OR (95% Cis) 1 1.731(0.945-3.172) 0.929(0.785-1.779) 2.073(0.486-8.836) 1.205(0.606-2.396) 0.670(0.386-1.163) 
        
ADJUSTED ODDS OF PCI > 60 DAYS*** OR (95% Cis) 1 1.128(0.682-1.866) 0.792(0.433-1.449) 1.051(0.381-2.902) 1.196(0.623-2.298) 0.638(0.369-1.105) 
        
ADJUSTED ODDS OF PCI > 60 DAYS*** OR (95% Cis) 1 1.568(0.831-2.958) 0.851(0.419-1.729) 2.094(0.465-9.422) 1.027(0.482-2.187) 0.591(0.312-1.118) 
        
1 Kruskall Wallis test 
2 Pearson’s Chi-squared test 
* Intervals are restricted to 0-730 days and any intervals out with this range are excluded to minimise data errors.. Additionally, where relevant valid dates are not 




Supplementary TABLE S10: DIAGNOSTIC INTERVAL BY 6-FOLD URBAN RURAL CLASSIFCATION (n=1572)* 




Other Urban Areas 
N=374* 
n(%) 
Accessible Small Towns 
N=166* 
n(%) 
Remote Small Towns 
N=54* 
n(%) 
Accessible Rural Areas 
N=187* 
n(%) 
Remote Rural Areas 
N=194* 
n(%) 
DIAGNOSTIC INTERVAL (IQR) MEDIAN (IQR) 29(12-67) 28(13-64) 31(15-64) 23(11-66.75) 30(14-61) 35.5(14.75-87) 
       P=0.1331 
DIAGNOSTIC INTERVAL > 60 DAYS YES 166(27.8) 98(26.2) 46(27.7) 16(29.6) 47(25.1) 72(37.1) 
 NO 431(72.2) 276(73.8) 120(72.3) 38(70.4) 140(74.9) 122(62.9) 
       P=0.0972 
DIAGNOSTIC INTERVAL > 60 DAYS YES 106(17.8) 58(15.5) 31(18.7) 8(14.8) 30(16.0) 47(24.2) 
 NO 491(82.2) 316(84.5) 135(81.3) 46(85.2) 157(84.0) 147(75.8) 
       P=0.1782 
UNADJUSTED ODDS OF DI > 60 DAYS OR (95% Cis) 1 1.059(0.794-1.411) 0.922(0.635-1.339) 0.889(0.491-1.610) 1.125(0.779-1.632) 0.636 (0.456-0.889) 
        
UNADJUSTED ODDS OF DI > 90 DAYS OR (95% Cis) 1 1.142(0.811-1.609) 0.844(0.552-1.291) 1.150(0.548-2.414) 1.113(0.720-1.722) 0.647(0.443-0.944) 
        
ADJUSTED ODDS OF DI > 60 DAYS*** OR (95% Cis) 1 1.048(0.768-1.430) 0.954(0.631-1.443) 0.930(0.486-1.779) 1.159(0.764-1.757) 0.620(0.422-0.911) 
        
ADJUSTED ODDS OF DI > 90 DAYS*** OR (95% Cis) 1 1.094(0.760-1.575) 0.850(0.535-1.352) 1.231(0.559-2.709) 1.10(0.681-1.779) 0.641(0.416-0.988) 
        
1 Kruskall Wallis test 
2 Pearson’s Chi-squared test 
* Intervals are restricted to 0-730 days and any intervals out with this range are excluded to minimise data errors. Additionally, where relevant valid dates are not available 





Supplementary TABLE S11: SECONDARY CARE INTERVAL BY 6-FOLD URBAN RURAL CLASSIFCATION (n=977)* 




Other Urban Areas 
N=203 
 n(%)* 
 Accessible Small Towns 
N=113 
n(%)* 
Remote Small Towns 
N=35 
n(%)* 
Accessible Rural Areas 
N=110 
n(%)* 
Remote Rural Areas 
N=132 
n(%)* 
SECONDARY CARE INTERVAL (IQR) MEDIAN (IQR) 62.5(34-109) 62(38-95) 56(36.5-104) 63(34-138) 61.5(33-98.25) 62.5(34-106.75) 
       P=0.9901 
SECONDARY CARE INTERVAL > 60 DAYS YES 199(51.8) 105(51.7) 53(46.9) 18(51.4) 56(50.9) 68(51.5) 
 NO 185(48.2) 98(48.3) 60(53.1) 17(48.6) 54(49.1) 64(48.5) 
       P=0.9692 
SECONDARY CARE INTERVAL > 90 DAYS YES 129(33.6) 58(28.6) 35(31.0) 13(37.1) 36(32.7) 48(36.4) 
 NO 255(66.4) 145(71.4) 78(69.0) 22(62.9) 74(67.3) 84(63.6) 
       P=0.7022 
UNADJUSTED ODDS OF SCI > 60 DAYS OR (95% Cis) 1 0.985(0.702-1.381) 1.180(0.779-1.788) 1.005(0.503-2.008) 1.026(0.672-1.568) 1.018(0.688-1.507) 
        
UNADJUSTED ODDS OF SCI > 90 DAYS OR (95% Cis) 1 1.221(0.846-1.764) 1.072(0.687-1.671) 0.849(0.414-1.741) 1.032(0.657-1.620) 0.881(0.585-1.327) 
        
ADJUSTED ODDS OF SCI > 60 DAYS*** OR (95% Cis) 1 0.889(0.606-1.302) 1.175(0.722-1.912) 1.320(0.597-2.915) 1.054(0.637-1.743) 1.098(0.690-1.749) 
        
ADJUSTED ODDS OF SCI > 90 DAYS*** OR (95% Cis) 1 1.139(0.751-1.727) 1.056(0.625-1.786) 1.073(0.464-2.478) 1.079(0.628-1.852) 0.969(0.592-1.589) 
        
1 Kruskall Wallis test 
2 Pearson’s Chi-squared test 
* Intervals are restricted to 0-730 days and any intervals out with this range are excluded to minimise data errors. Additionally, where relevant valid dates are not available 
intervals could not be calculated.   
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Supplementary TABLE S12: TREATMENT INTERVAL BY 6-FOLD URBAN RURAL CLASSIFCATION (n=1223)* 




Other Urban Areas 
N=271* 
 n(%) 
 Accessible Small Towns 
N=137* 
n(%) 
Remote Small Towns 
N=41* 
n(%) 
Accessible Rural Areas 
N=137* 
n(%) 
Remote Rural Areas 
N=154* 
n(%) 
TREATMENT INTERVAL (IQR) MEDIAN (IQR) 42(20-71) 37(20-60) 35(18-70) 43(25-86.5) 36(20.5-69.5) 39(14-66.25) 
       P=0.4781 
TREATMENT INTERVAL > 60 DAYS YES 150(31.1) 67(24.7) 42(30.7) 16(39.0) 35(25.5) 47(30.5) 
 NO 333(68.9) 204(75.3) 95(69.3) 25(61.0) 102(74.5) 107(69.5) 
       P=0.2602 
TREATMENT INTERVAL > 60 DAYS YES 86(17.8) 35(12.9) 24(17.5) 10(24.4) 21(15.3) 20(13.0) 
 NO 397(82.2) 236(87.1) 113(82.5) 31(75.6) 116(84.7) 134(87.0) 
       P=0.2562 
UNADJUSTED ODDS OF TI > 60 DAYS OR (95% Cis) 1 1.397(0.999-1.952) 1.020(0.678-1.536) 0.793(0.418-1.503) 1.274(0.830-1.958) 1.051(0.711-1.554) 
        
UNADJUSTED ODDS OF TI > 90 DAYS OR (95% Cis) 1 1.485(0.972-2.269) 1.021(0.621-1.679) 0.740(0.353-1.550) 1.167(0.694-1.963) 1.479(0.877-2.496) 
        
ADJUSTED ODDS OF TI > 60 DAYS*** OR (95% Cis) 1 1.239(0.855-1.796) 0.851(0.526-1.376) 0.708 (0.338-1.480) 1.128(0.687-1.854) 0.863(0.545-1.367) 
        
ADJUSTED ODDS OF TI > 60 DAYS*** OR (95% Cis) 1 1.395(0.874-2.228) 0.849(0.470-1.531) 0.663(0.278-1.582) 1.033(0.566-1.884) 1.224(0.667-2.243) 
        
1 Kruskall Wallis test 
2 Pearson’s Chi-squared test 
* Intervals are restricted to 0-730 days and any intervals out with this range are excluded to minimise data errors. Additionally, where relevant valid dates are not available 
intervals could not be calculated.   
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